Four years after the approval of Trikafta (elexacaftor/tezacaftor/ivacaftor) for cystic fibrosis (CF), global disparities in access to the…
Articles by Andrea Lobo, PhD
A history of pancreatic inflammation, diabetes, high blood pressure, and high cholesterol may increase the risk of pancreatic cancer in…
People with advanced liver disease associated with cystic fibrosis (CF) have more pro-inflammatory bacteria in their feces relative to those…
A greater increase in body mass index (BMI), a measure of body fat, from ages 1 through 6…
The nasal microbiome — the community of microorganisms that live in the nose — obtained through nasal lavage…
Clarametyx Biosciences has completed a $33 million financing round to support its development of CMTX-101, a non-antibiotic treatment candidate for…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to BX004, BiomX’s inhaled phage therapy being…
Treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) improved the pancreatic function of two women with cystic fibrosis (CF), allowing them to…
Mental health issues — namely, attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) — in children with cystic fibrosis…
Blood levels of an indicator of diabetes, glycated hemoglobin (HbA1c), fell within the first year that cystic fibrosis (CF)…